Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis

Luigi Gennari, Daniela Merlotti, Konstantinos Stolakis, Ranuccio Nuti

Research output: Contribution to journalArticlepeer-review


Introduction: Toremifene is a triphenylethylene selective estrogen receptor modulator (SERM) that differs from tamoxifen in a single chloride ion addition on a side chain, resulting in a potentially more favorable toxicity profile. Areas covered: This article reviews the pharmacokinetics of toremifene and its potential use for the treatment of osteoporosis. This article was based on articles found through a literature search containing the terms 'toremifene' and 'SERMs.' Expert opinion: Toremifene can be administered orally with an excellent bioavailability. The overall pharmacokinetic profile is remarkably similar to tamoxifen. Toremifene is highly metabolized in the liver and is eliminated primarily in the feces following enterohepatic circulation. Some of its metabolites retain biological activity. This SERM was approved by the FDA for the treatment of estrogen receptor-positive metastatic breast cancer and is under investigation for its potential skeletal benefits in men on androgen deprivation therapy. Despite the positive preclinical and clinical evidences for the prevention of bone loss and fractures, the chemopreventive effect on prostate cancer remains to be confirmed and an increased risk of venous thromboembolism was evidenced in a large Phase III trial. Thus, additional data are required to establish the full clinical profile of this compound and its potential advantages over antiresorptive agents commonly in use for the treatment of osteoporosis.

Original languageEnglish
Pages (from-to)505-513
Number of pages9
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number4
Publication statusPublished - Apr 2012


  • Metabolism
  • Osteoporosis
  • Pharmacokinetics
  • SERM
  • Toremifene

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis'. Together they form a unique fingerprint.

Cite this